Anti Beta Alzheimer Therapies Market, by Drug (Aducanumab, Bapineuzumab, Solanezumab), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
Select a License Type that Suits your Business Needs
Excel Databook
US$ 2,200
Two thousand two hundred dollars
Dashboard with market estimates and forecast
Raw Data Sheet providing cross-sectional analysis
Leading Players Positioning Matrix
All segments/taxonomy covered (Statistics)
Single User License
( Full Report )
US$ 4,500
US$ 2,500
Two thousand five hundred dollars
Report accessible by 1 user only
Free 20% or 35 hours of customisation
Free post-sale service assistance
Direct access to lead analyst
Frequently purchased
Multi User License
( Full Report )
US$ 7,000
US$ 3,850
Three thousand five hundred dollars
Report accessible by 7 users
Free 30% or 70 hours of customisation
Free post-sale service assistance
Direct access to lead analysts
25% discount on your next purchase
Dedicated account manager
Personalized market brief by the lead author, if needed
Printable version of the report
Corporate User License
( Full Report )
US$ 10,000
US$ 6,000
Seven thousand five hundred dollars
Report accessible to unlimited users
Free 35% or 85 hours of customisation
Free post-sale service assistance
Direct access to lead analysts
30% discount on your next purchase
Dedicated account manager
Personalized market brief by the lead author, if needed
Anti Beta Alzheimer Therapies Market, by Drug (Aducanumab, Bapineuzumab, Solanezumab), and by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) - Global Industry Insights, Trends, Outlook, and Opportunity Analysis, 2022-2028
U.S.: 
U.K. : 
AUS : 
INDIA :